Medical condition
Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy is a medical condition tracked by NovaPharmaNews across 6 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- eteplirsen (EXONDYS) Musculo-skeletal system (M09)
- vamorolone (AGAMREE) Systemic hormonal preparations (H02)
- givinostat (DUVYZAT) Musculo-skeletal system (M09)
- idebenone (RAXONE) Nervous system (N06)
- ataluren (TRANSLARNA) Musculo-skeletal system (M09)
- delandistrogene moxeparvovec (ELEVIDYS) Musculo-skeletal system (M09)
Latest Duchenne Muscular Dystrophy news
Capricor Therapeutics HOPE-3 Phase 3 Trial Results for Deramiocel in Duchenne Muscular Dystrophy to be Presented at AAN 2026
Capricor Therapeutics announces late-breaking presentation of HOPE-3 Phase 3 trial results for Deramiocel in Duchenne muscular dystrophy at AAN 2026.
Medera's AAV-SERCA2a Gene Therapy Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Cardiomyopathy
Medera Inc. receives FDA Fast Track designation for AAV-SERCA2a gene therapy targeting cardiomyopathy in Duchenne muscular dystrophy patients.